Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma.
An isocratic reversed-phase high-performance liquid chromatography method with UV detection is developed and validated for the simultaneous determination of ketamine, xylazine, and midazolam in canine plasma. Analytes are extracted from alkalinized samples into diethyl ether-methylene chloride (7:3, v:v) using single-step liquid-liquid extraction. Chromatographic separation is performed on a C(18) column using a mobile phase containing an acetonitrile-methanol-10 mM sodium heptanesulfonate buffer adjusted to pH 3, with glacial acetic acid (44:10:46, v:v) at a detection wavelength of 210 nm, with a total runtime of 10 min. The calibration is linear over the range of 78.125-5000 ng/mL for ketamine and 15.625-1000 ng/mL for xylazine and midazolam. The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively. The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine. The method is successfully used for clinical and pharmacokinetic studies of the three-drug fixed dose combination formulations.
College of Veterinary Medicine, Nanjing Agricultural University, 210095 Nanjing, China.
Peide
P
Li
Hangru
H
Han
Xiaohu
X
Zhai
Weihua
W
He
Liying
L
Sun
Jiafa
J
Hou
D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004285:Dogs; D005260:Female; D007649:Ketamine / Q000097:blood*; D008297:Male; D008874:Midazolam / Q000097:blood*; D013056:Spectrophotometry, Ultraviolet / Q000379:methods*; D014991:Xylazine / Q000097:blood*
D014991:Xylazine; D007649:Ketamine; D008874:Midazolam